StockpollyBeta
Get App
Popularity #1,203
BHVN · NYSE · Biotechnology

Biohaven (BHVN)

Develops prioritized drug programs in epilepsy, immunology, and obesity.

$14.85
After hours−0.02 (−0.13%)
At close$14.87(+4.57%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue010000001100
Gross profit0−1000000−1−100
111153183334178190222212168142130125
Research & development96135156315158167188184141122104101
151827192122342728212724
Selling & marketing0−10000000000
General & administrative151927192122342728212724
Other expenses00000000−1−100
Operating income−111−154−183−334−178−190−222−212−169−143−130−125
58414183014−4−20−12
Interest income464566443300
Other non-operating income0−8−4−14−18−30−1442012
Income before tax−106−146−179−320−160−187−221−198−173−145−130−137
Income tax expense−3−11000100000
Net income from continuing operations−103−145−180−320−160−187−222−198−173−146−131−137
Net income−103−145−180−320−160−187−222−198−173−146−131−137
EPS, basic−$1.50−$1.81−$2.20−$3.64−$1.70−$1.85−$2.17−$1.94−$1.64−$1.21−$0.88−$0.91
EPS, diluted−$1.50−$1.81−$2.20−$3.64−$1.70−$1.85−$2.17−$1.94−$1.64−$1.21−$0.88−$0.91
Weighted average shares, basic6880828894101102102106120148151
Weighted average shares, diluted6880828894101102102106120148151
EBITDA−109−144−177−318−158−184−219−196−172−143−128−132
Depreciation & amortization221222221325
EBIT−111−146−179−320−160−187−221−198−173−145−130−137